Dr. Aysun Ertaş
Check-ups & DiagnosticsVerified
- 23+years exp.
English · Turkish
FromPrice on request
Free quote
60 seconds · no obligationView Profile
Imaging (MRI, CT, PET)
Gallium-68 dota pet-ct
What a Gallium-68 DOTA PET-CT scan is, how somatostatin receptor radiotracers target neuroendocrine tumours, what clinical evidence says about diagnostic accuracy, how it compares with FDG PET and Octreoscan, approximate costs in Turkey compared with the UK, US and Germany, how to prepare, radiation safety, who suits the scan and what questions to ask your medical team.
A written plan with the surgeon's name and the full price — usually within 24 hours.
- Category
- Imaging (MRI, CT, PET)
- Hospitals
- 2
- Verified
- 2
- Price from
- Price on request
Verified surgeons for Gallium-68 DOTA PET-CT
2 doctors Compare doctors, ratings and prices — ask any of them for a free quote.
Uzm. Dr. Türkan Özer
Check-ups & DiagnosticsVerified
- 47+years exp.
English · Turkish
FromPrice on request
Free quote
60 seconds · no obligationView Profile
Gallium-68 DOTA PET-CT in Turkey: what it is and how it works
A gallium-68 dota pet-ct scan is a specialised molecular imaging procedure used to detect, stage, and monitor neuroendocrine tumours (NETs). Unlike standard scans that show only anatomy, this examination combines positron emission tomography (PET) with computed tomography (CT) using a targeted radiotracer. The tracer pairs the positron-emitting isotope Gallium-68 with a DOTA chelator and a somatostatin analogue peptide, such as DOTATATE or DOTATOC. Because neuroendocrine cells overexpress somatostatin receptors, the tracer binds directly to these targets, highlighting abnormal lesions with high clarity.
Hospitals in Turkey offer gallium-68 dota pet-ct in Turkey for international patients seeking prompt diagnosis, staging of metastases, or evaluation for peptide receptor radionuclide therapy (PRRT). This guide explains how receptor imaging works, what evidence shows, approximate costs across Turkey, the UK, the US, and Germany, and what to expect during your appointment. For an overview of imaging options, explore our guide to checkup treatments in Turkey.
How does a Gallium-68 DOTA PET-CT scan detect neuroendocrine tumours?
The mechanism behind gallium-68 dota pet-ct relies on molecular targeting. Most well-differentiated neuroendocrine tumours—arising in the digestive tract, pancreas, or lungs—display dense somatostatin subtype-2 receptors (SSTR2). The diagnostic radiopharmaceutical mimics natural somatostatin. Injected intravenously, it circulates and binds specifically to these receptors, concentrating the Gallium-68 isotope at tumour sites.
Gallium-68 decays with a half-life of 68 minutes, emitting positrons. When a positron collides with an electron in tissue, they annihilate, releasing two 511 keV gamma photons in opposite directions. The PET ring detects these coincident photons to map tracer concentrations in three dimensions. Simultaneously, the CT scanner captures anatomical cross-sections. Software fuses the metabolic PET signals onto the CT images, enabling nuclear medicine physicians to pinpoint exact tumour locations.
Does Gallium-68 DOTA PET-CT imaging actually work?
Clinical evidence demonstrates that Gallium-68 DOTA PET-CT is an accurate imaging modality for neuroendocrine neoplasms. Guidelines from the European Association of Nuclear Medicine (EANM) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) confirm sensitivity and specificity exceeding 90% for well-differentiated (Grade 1 and Grade 2) tumours. It reliably detects small primary lesions, lymph node spread, and bone or liver metastases that standard CT or ultrasound can miss.
However, the scan has biological limitations. Its accuracy depends on active somatostatin receptor expression. In fast-growing, high-grade (Grade 3) neuroendocrine carcinomas, tumour cells often lose these receptors while consuming more glucose; in those cases, FDG PET-CT provides clearer diagnostic value. Normal physiological tracer uptake also occurs in the spleen, kidneys, adrenal glands, pituitary gland, and liver, which specialists must distinguish from disease. A reputable clinic will never promise that a scan detects every cellular abnormality without histological confirmation.
Gallium-68 DOTA PET-CT cost in Turkey compared with the UK, US and Germany
The figures below provide approximate cost ranges for a single diagnostic PET-CT session. These numbers represent typical self-pay prices and are not hospital quotes. Pricing varies depending on the specific radiopharmaceutical synthesised, whether intravenous CT contrast is administered, and the clinical scope of the study.
| Country | Approximate cost range |
|---|---|
| Turkey | €1,400 – €2,800 |
| United Kingdom | €3,200 – €6,500 |
| United States | €5,500 – €12,000 |
| Germany | €2,800 – €5,800 |
Several factors influence gallium-68 dota pet-ct cost. The primary driver is tracer production: Gallium-68 must be freshly synthesised from a generator or cyclotron on the morning of your scan. The gallium-68 dota pet-ct price also reflects multi-slice CT contrast, expert interpretation, and expedited reporting. In Turkey, medical packages commonly include local transfers, translation assistance, radiopharmaceutical synthesis, scanner fees, and a digital DICOM disc; always request an itemised written quotation.
Gallium-68 DOTA PET-CT vs 18F-FDG PET and Octreoscan
Selecting the right nuclear scan depends on tumour biology, grading, and receptor status. Historical imaging relied on Indium-111 pentetreotide (Octreoscan) scintigraphy, whereas contemporary oncology utilises advanced hybrid PET-CT systems with distinct radiotracers.
| Method | Best suited to | Typical limits |
|---|---|---|
| Gallium-68 DOTA PET-CT | Well-differentiated NETs (G1 and G2) expressing somatostatin receptors; PRRT staging | Less sensitive for poorly differentiated or G3 tumours lacking SSTR expression |
| 18F-FDG PET-CT | High-grade, rapidly proliferating G3 NETs, neuroendocrine carcinomas, glycolytic tumours | Poor detection of slow-growing, low-grade NETs with normal glucose metabolism |
| Indium-111 Octreotide (SPECT) | Conventional somatostatin receptor scintigraphy where PET-CT is unavailable | Lower spatial resolution, higher radiation exposure, requires multi-day scanning |
Compared to legacy planar Octreoscan scintigraphy, Gallium-68 DOTA PET-CT offers higher spatial resolution (detecting lesions down to 3 to 5 millimetres), shorter imaging times (one hour versus two to three days), and lower radiation exposure. When assessing heterogeneous tumours, oncologists occasionally order both Gallium-68 DOTA and FDG PET-CT scans to evaluate differing cellular behaviours across lesions.
Who is a candidate for Ga-68 DOTA imaging, and who is not?
A gallium-68 dota pet-ct scan suits patients with confirmed or suspected neuroendocrine neoplasms. Typical indications include initial staging of gastrointestinal, bronchial, or pancreatic NETs, localising an occult primary tumour when biomarkers are elevated, restaging after surgery, and determining eligibility for peptide receptor radionuclide therapy (PRRT) with Lutetium-177 DOTATATE.
The scan is not intended for general cancer screening or asymptomatic individuals without clinical suspicion of neuroendocrine disease. While routine diagnostic screenings like mammography or plain ultrasound detect structural abnormalities, Gallium-68 DOTA imaging tracks specific molecular receptors. Pregnant women should avoid PET-CT scans unless the diagnostic benefit decisively outweighs fetal radiation risks. Breastfeeding mothers require temporary interruption of nursing following tracer injection. Furthermore, patients receiving long-acting somatostatin analogues (such as octreotide LAR or lanreotide) may experience receptor saturation, which reduces scan sensitivity unless scheduled 3 to 4 weeks after their last injection.
What happens during the scan: preparation and procedure step by step
Preparation for a gallium-68 dota pet-ct scan is straightforward. Fasting is usually unnecessary, though drinking plain water beforehand is encouraged to ensure good hydration. If you take somatostatin analogue medication, your oncology team will advise whether to time the scan just before your next dose. Patients travelling from abroad can review how it works to coordinate schedules.
The procedure follows four straightforward steps:
- Injection: A clinician places an intravenous cannula and administers the Gallium-68 DOTA tracer over one to two minutes.
- Uptake: You rest in a private room for 45 to 60 minutes while the tracer circulates and binds to somatostatin receptors.
- Voiding: You empty your bladder immediately before entering the scanner room to clear background pelvic activity.
- Scanning: You lie flat on the scanner bed while the integrated PET and low-dose CT images are captured over 20 to 30 minutes.
Before and after the scan: what results show and what they cannot
The fused PET-CT images provide qualitative and quantitative diagnostic information. Abnormal tracer accumulation appears as bright hotspots against normal tissue. Physicians assess these areas using Standardised Uptake Values (SUVmax), which reflect receptor density. High uptake in lymph nodes, liver, peritoneum, or bones confirms metastatic involvement and helps clinicians choose appropriate medical or surgical therapies.
Understanding what scan results cannot show is equally important. A PET-CT scan does not replace a histological biopsy and cannot differentiate tumour grades on its own. Moreover, benign inflammatory conditions, surgical healing, or thyroid adenomas can occasionally express somatostatin receptors, causing false-positive readings. Conversely, sub-centimetre lesions with low receptor density may fall below scanner detection thresholds. Findings must always be correlated with clinical history, laboratory markers, and tissue pathology.
Your trip to Turkey and gallium-68 dota pet-ct recovery
Because the procedure is non-invasive and requires no sedation or incisions, gallium-68 dota pet-ct recovery is immediate. You can eat, drink, and return to normal activities right after the scan. Patients booking gallium-68 dota pet-ct Turkey appointments typically spend two to three nights in the country to complete the scan, receive their digital DICOM disc, and obtain an English radiology report. Combining molecular scans with broader health assessments is detailed in our checkup treatments in Turkey guide.
Post-scan precautions focus on eliminating radioactivity. Drink plenty of water over the next 24 hours to promote urinary excretion. Wash your hands thoroughly with soap after using the toilet. Avoid close contact with pregnant women and infants for 10 to 12 hours. Flying home the next day is safe; carry your medical report, as airport radiation monitors can occasionally detect trace activity within 24 hours.
Risks, radiation exposure and safety precautions
Diagnostic Gallium-68 DOTA PET-CT is a safe examination with minimal clinical risks. Diagnostic radiotracers use minute chemical quantities that do not cause pharmacological side effects, and allergic reactions to the peptide compound are extraordinarily rare. If intravenous iodinated CT contrast is co-administered, standard contrast precautions apply; patients with impaired renal function or known iodine allergies must notify staff beforehand.
Radiation exposure is the main consideration in nuclear imaging. According to guidelines from the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the International Commission on Radiological Protection (ICRP), the effective dose from the Gallium-68 tracer is approximately 3 to 5 millisieverts (mSv). The low-dose CT component adds 2 to 5 mSv, resulting in a total combined dose of 5 to 10 mSv. This level is comparable to standard diagnostic abdominal CT and remains well within recognised international safety margins.
How to choose a nuclear medicine centre and red flags to watch for
Booking nuclear imaging abroad requires verifying clinic standards, imaging equipment, and clinical credentials. Because Gallium-68 has a 68-minute half-life, the hospital must have an on-site radiopharmacy or reliable daily generator supply. Ensure scans are interpreted by certified nuclear medicine physicians with neuroendocrine experience. Before travelling, you can submit your medical records to request a free quote from accredited hospitals.
Red flags to watch for when choosing a facility:
- Unclear tracer details: Inability to specify whether 68Ga-DOTATATE or 68Ga-DOTATOC is used, or lack of on-site quality controls.
- Outdated imaging technology: Stand-alone PET cameras without integrated multi-slice CT capabilities.
- Hidden costs: Quotations that exclude tracer synthesis, radiologist fees, or English reports.
- No oncological support: Centres lacking links to multidisciplinary tumour boards or medical oncologists.
Key questions to ask the clinic before booking:
- Which specific DOTA radiotracer is used for the scan?
- Is the study interpreted by a board-certified nuclear medicine physician?
- Does the quotation include the tracer dose, CT contrast, and an English report?
- How quickly will I receive the DICOM digital image files on disc?
- Can your multidisciplinary tumour board review the findings if treatment is needed?
Reviewing how it works helps you coordinate medical record transfers, while requesting an estimate through our free quote service connects you directly with accredited Turkish diagnostic departments.
Hospitals with Check-ups & Diagnostics in Turkey
Frequently asked questions
A Gallium-68 DOTA PET-CT scan is a molecular imaging procedure that detects neuroendocrine tumours. A positron-emitting Gallium-68 isotope is attached to a somatostatin analogue peptide such as DOTATATE. This radiotracer binds to somatostatin receptors on tumour cells, allowing high-resolution PET and CT cameras to pinpoint small primary lesions and metastases throughout the body.
Yes, clinical guidelines recognise it as a highly sensitive diagnostic tool for well-differentiated neuroendocrine tumours expressing somatostatin receptors. It provides clearer lesion detection and staging than conventional scintigraphy or standard CT. However, it is less effective for high-grade or dedifferentiated tumours that have lost somatostatin receptor expression, where FDG PET-CT is typically used instead.
The scan typically costs between €1,400 and €2,800 in Turkey, compared to €3,200 to €6,500 in the UK and higher in the US. The price varies according to the radiotracer used, whether intravenous CT contrast is administered, and if rapid reporting or specialist consultations are included in the clinic package.
The scan produces cross-sectional and three-dimensional images showing abnormal radiotracer uptake, measured as standard uptake values. These indicate where neuroendocrine tumours and metastases are located. It also evaluates somatostatin receptor density, which determines whether you are a suitable candidate for targeted radionuclide therapy such as Lutetium-177 DOTATATE.
Gallium-68 DOTA targets somatostatin receptors abundant on slow-growing, well-differentiated neuroendocrine cells. In contrast, 18F-FDG PET measures glucose metabolism and is more sensitive for fast-growing, aggressive high-grade tumours. In complex or intermediate-grade cases, oncologists sometimes order both scans together to assess whether tumour lesions have differing biological behaviours.
The scan itself is non-invasive and causes no physical discomfort. The only physical step is the initial insertion of a small intravenous cannula in your arm for the radiotracer injection and contrast dye. You will need to lie still on the scanner table for approximately twenty to thirty minutes during image acquisition.
There is no medical downtime, and you can resume normal daily activities immediately after the scan. Because Gallium-68 has a short half-life of sixty-eight minutes, the radioactive tracer decays rapidly. Drinking plenty of fluids over the first twenty-four hours speeds up the clearance of any remaining tracer through your urine.
The combined radiation exposure from the Gallium-68 tracer and the low-dose CT component is approximately five to ten millisieverts, comparable to standard abdominal CT imaging. Nuclear medicine societies consider this level safe for diagnostic use. As a precaution, patients should avoid prolonged close contact with pregnant women and young infants for twelve hours.
Scan findings reflect disease distribution at the time of imaging. For stable, low-grade neuroendocrine tumours, results frequently guide clinical management for six to twelve months. If symptoms change, biochemical markers rise, or before starting a new systemic treatment, your oncologist may recommend a follow-up scan to assess disease progression.
Most patients need to spend two to three nights in Turkey. This schedule allows time for arrival, an initial consultation, the scan itself, and receiving your digital image disc and English radiology report. Staying an extra day provides time to discuss the findings directly with an oncologist or nuclear medicine specialist.
Patient stories